Bell Potter Healthcare Conference

Andrew Shute (Sr Vice President, Business Development)

20 November 2024

Disclaimer

The material contained in this document is a presentation of general information about the activities of EBR Systems, Inc. (ASX:EBR) (ARBN 654 147 127) and its subsidiaries ("EBR") current as at the date of this presentation. It should be read in conjunction with EBR's periodic and continuous disclosure announcements filed with the Australian Securities Exchange, available at www.asx.com.au.

The information in this presentation is provided in a summary form, does not purport to be complete and should not be relied upon as advice for investment purposes. This presentation is for information purposes only and is not financial product advice or a recommendation to acquire EBR securities. This presentation does not take into account the investment objectives, financial position or needs of any particular investor. Independent advice should be sought before making any investment decision.

The information in this presentation has been prepared by EBR in good faith and with due care, but the EBR does not make any representation or warranty, express or implied, as to the fairness, accuracy, correctness or completeness of the information, opinions or conclusions contained in this presentation. The information in this presentation is subject to change without notice and unless required by law, EBR assumes no obligation to update this presentation or its contents for any matter arising or coming to EBR's notice after the date of this presentation.

Certain statements in this presentation may constitute forward-looking statements or statements about future matters that are based on management's current expectations and beliefs. Such statements are typically identified by words such as 'may', 'could', 'believes', 'estimates', 'expects', 'anticipates', 'intends' and other similar words. These statements are subject to risks and uncertainties that are difficult to predict and are based on assumptions as to future events that may not prove accurate. Actual results may differ materially from what is expressed in this presentation.

To the maximum extent permitted by law, no responsibility for any loss arising in any way (including by way of negligence) from anyone acting or refraining to act as a result of this presentation or its contents is accepted by EBR or any of its officers, employees or agents.

The distribution of this presentation outside of Australia may be restricted by law and any such restrictions should be observed. This presentation does not constitute an offer to sell, or a solicitation of an offer to buy, securities in Australia, the United States or any other jurisdiction.

Investors should note that this presentation may contain unaudited financial information that has been prepared by EBR's management. EBR's results are reported under US GAAP. Certain financial data in this presentation is "non-IFRS financial information" under Regulatory Guide 230 (Disclosing non-IFRS financial information) published by ASIC. All values are stated in U.S. dollars unless otherwise stated.

EBR's CHESS Depositary Interests ("CDIs") are traded on ASX in reliance on the safe harbour provisions of Regulation S under the US Securities Act of 1933, as amended, and in accordance with the procedures established pursuant to the provisions of a no-action letter dated 7 January 2000 given to ASX by the staff at the US Securities and Exchange Commission. The relief was given subject to certain procedures and conditions described in the no-action letter. One of the conditions is that the issuer provides notification of the Regulation S status of its securities in communications such as this presentation.

Investment highlights

Developer of the world's first and only leadless pacemaker for heart failure

High value market opportunity

Unique solution

No competition as the WiSE CRT system is complementary to other leadless devices. It is the only leadless device to deliver CRT

Large markets

Targeting an initial addressable market of US$3.6bn

Pathways to market

Positive results

Safety and efficacy endpoints met for SOLVE-CRT trial and Breakthrough Device Designation granted

Clear pathway to FDA approval

Final PMA module submitted to FDA. Approved expected in Q1 2025.

Defined Strategy



Clear commercial strategy in place

Progressing commercialisation activities to initial revenue in CY2025 by targeting high-volume sites in the US

Traditional CRT systems are suboptimal

Traditional CRT systems use wires or leads to deliver energy to the heart, which can lead to many problems.

- Leads can migrate and sometimes fracture
- Leads can become a way for pathogens to reach the myocardium
- Difficult to place



- LV lead must be placed outside the heart to avoid blood clots
- Coronary Sinus limits Left Ventricle (LV) lead placement locations
- Leads can be associated with phrenic nerve stimulation

EBR has a wireless solution for the heart

EBR's WiSE CRT System is the only wireless device that can deliver cardiac resynchronisation therapy

WiSE CRT System fills the gap

The only leadless solution for left ventricle (LV) pacing

Other wireless pacemakers are too big for LV pacing

Their size increases the risk of blood clots, restricting their use to right ventricle (RV) and right atrium (RA) pacing only

Complementary solution

WiSE CRT System can be used in conjunction with wireless RV / RA pacemakers to deliver CRT

Strong competitive protection

WiSE CRT System is protected by over 97 issued patents globally

Left ventricle[1]

EBR Systems WiSE CRT System

Right ventricle / atrium[1]

Medtronic Micra®

Boston Scientific Empower®

Abbott Aveir®



Extravascular / Subcutaneous ICD

Boston Scientific Emblem®

Medtronic Aurora®

(1) Illustrative sizing (not to scale)

Commercialisation Pathway

Positive pivotal trial results and strong track record with the FDA provide a clear pathway to approval, reimbursement and commercialisation

Positive Clinical Results

Efficacy: -16.4% decrease in left ventricular systolic volume (vs -9.3% target), showing improved heart function[1]

Safety: 80.9% freedom from type I complications (vs 70% target)[1], increasing to 85.7% post mitigations[4]

PMA Submission

EBR has finalised its PMA submission to the FDA. Breakthrough Device Designation ensures prioritised review process:

- Filing acknowledgement
- 100-day meeting
- Biomedical Monitoring audit (BIMO)
- Pre-Approval Inspection (PAI)

Reimbursement

- Clear pathway to NTAP[2] and TPT[2] reimbursement schemes post FDA approval
- CMS issued WiSE specific CPT [2] codes
- CPT codes already assigned to interim APC[2] codes
- Defined process to reassign APC codes based on actual claims data
- WiSE CRT System target US ASP: US$45,000[3]

[1] "CEO Presentation on SOLVE-CRT Pivotal Trial Top-line Data" ASX release on 22 May 2023; [2] Standard of Care; [3] Poole, J. E., et al. (2010). Circulation 122(16): 1553-1561
[2]APC: Ambulatory Payment Classification, ASP: Average Selling Price, CMS: Centers for Medicare & Medicaid Services, CPT: Current Procedural Terminology, NTAP: New Technology Add-on Payment, TPT: Transitional Passthrough Payment; [3] U.S. pricing with New Technology Add-on Payment (NTAP) post-approval; [4]James S, et al. (2024). APHRS 2024 Abstract.

Initial commercialisation strategy

EBR will leverage its established partnerships and presence in the US to drive initial sales growth

Clinical trial sites to drive initial sales

- **2025:** Targeting US sites that have participated in the SOLVE-CRT trial and other high-volume sites with Key Opinion Leaders (KOLs)
- **2026+:** Target top 200 to 250 clinical sites, representing >50% US CRT market

Direct, specialist sales force

- Execution of commercial launch supported by specialised direct sales force to target high volume sites
- SOLVE-CRT core team in place with clinical and technical expertise of WiSE CRT System
- Grow initial sales and expand into new areas with sales force expansion over time

Manufacturing capabilities

- Manufacturing capabilities in place with cabability to meet early demand
- Expand in-house manufacturing facility to meet future demand

US$3.6bn initial addressable market

At commercial launch, EBR estimates an initial addressable market of ~US$3.6bn

Leadless Upgrades

- Patients with a leadless right ventricle pacemaker can only upgrade with WiSE CRT System to receive effective CRT
- WiSE CRT System paired with the Medtronic Micra (single chamber) or Abbott Aveir (single chamber) device

Further growth potential – see next slide



Acute Lead Failure

Unable to implant CRT wire in a new CRT patient.

High Risk Upgrades

Patient requiring CRT, but is deemed too high risk for a conventional CS lead placement

Chronic Lead Failure

Traditional CRT system implanted but has ceased to provide effective CRT

(1) Grand View Research – Leadless Pacemakers Market, Cardiac Rhythm Market, Cardiac Resynchronization Therapy Market, WiSE current indications

Totally Leadless CRT grows the market

Continued global growth and adoption of leadless RV pacemakers significantly expands EBR's market opportunity



Sources: WHO, U.S. Centre for Disease Control and Prevention, US Food and Drug Administration, Investor Presentations, Primary Interviews, Grand View Research – Leadless Pacemakers Market

Clinical development: Totally Leadless CRT

EBR is actively progressing activities to initiate studies to support expanded indication

Commercial benefits

- Increased adoption of leadless pacemakers expands the need for WiSE, including upgrading dual chamber leadless pacemakers
- Opportunity to build a new market as first-line therapy with de novo totally leadless CRT

Patient benefits

- Avoid complications associated with lifelong implant of transvenous pacing leads
- More physiological pacing therapy

Development status

- Initiate the TLC-AU study in Australia in early 2025



Upcoming milestones

EBR continues to achieve significant value catalysts and pave the way to future value creation

Delivered

- ✓ Headline data released at Heart Rhythm Society conference
- ✓ Randomised data presented at industry conferences including Asia-Pacific Heart Rhythm Society
- ✓ Publication of manuscript in a peer reviewed medical journal
- ✓ Additional sub-studies published using SOLVE-CRT dataset
- ✓ Final PMA module submitted to the FDA
  - ✓ Substantial review begun

Near term

- ❑ FDA approval in the US
  - ❑ 100-day meeting
  - ❑ BIMO audit
  - ❑ PAI
- ❑ Reimbursement established
- ❑ Commercial launch in the US
- ❑ Continued clinical publications
- ❑ Initiate ACCESS and TLC studies

Next steps

- ❑ Expand manufacturing facility
- ❑ Expand use of WiSE CRT System into new patient groups
- ❑ Drive adoption in US
- ❑ Clinical study of rechargeable battery